Literature DB >> 33349889

Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab.

Surina Frey1, Benjamin Kendziora, Julian Walter Holch, Lars Lindner, Lars E French, Andreas Wollenberg.   

Abstract

Entities:  

Keywords:  ITP; dupilumab; immune thrombocytopenic purpura; thrombocytopenia; atopic dermatitis

Mesh：

Substances：

Year:  2021        PMID： 33349889      PMCID： PMC9366505          DOI： 10.2340/00015555-3734

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  9 in total

1.  Advances in the pathophysiology of primary immune thrombocytopenia.

Authors:  María Perera; Teresa Garrido
Journal:  Hematology       Date:  2016-09-27       Impact factor: 2.269

2.  Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Authors:  A Wollenberg; S Barbarot; T Bieber; S Christen-Zaech; M Deleuran; A Fink-Wagner; U Gieler; G Girolomoni; S Lau; A Muraro; M Czarnecka-Operacz; T Schäfer; P Schmid-Grendelmeier; D Simon; Z Szalai; J C Szepietowski; A Taïeb; A Torrelo; T Werfel; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-06       Impact factor: 6.166

3.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Authors:  Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal:  N Engl J Med       Date:  2016-09-30       Impact factor: 91.245

Review 4.  Dupilumab for treatment of atopic dermatitis.

Authors:  Marlene Seegräber; Jerome Srour; Alexandra Walter; Macarena Knop; Andreas Wollenberg
Journal:  Expert Rev Clin Pharmacol       Date:  2018-03-20       Impact factor: 5.045

5.  [Psoriasis in dupilumab-treated atopic dermatitis].

Authors:  S Senner; L Eicher; N Aszodi; J C Prinz; L E French; A Wollenberg
Journal:  Hautarzt       Date:  2020-05       Impact factor: 0.751

6.  ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.

Authors:  A Wollenberg; A Oranje; M Deleuran; D Simon; Z Szalai; B Kunz; A Svensson; S Barbarot; L von Kobyletzki; A Taieb; M de Bruin-Weller; T Werfel; M Trzeciak; C Vestergard; J Ring; U Darsow
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-03-23       Impact factor: 6.166

7.  High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Hatsue Ogawara; Hiroshi Handa; Kimio Morita; Masaki Hayakawa; Junko Kojima; Hatsuo Amagai; Yuki Tsumita; Yoriaki Kaneko; Norifumi Tsukamoto; Yoshihisa Nojima; Hirokazu Murakami
Journal:  Eur J Haematol       Date:  2003-10       Impact factor: 2.997

Review 8.  Approach to the diagnosis and management of drug-induced immune thrombocytopenia.

Authors:  Donald M Arnold; Ishac Nazi; Theodore E Warkentin; James W Smith; Lisa J Toltl; James N George; John G Kelton
Journal:  Transfus Med Rev       Date:  2013-07-08

9.  Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).

Authors:  A Wollenberg; L A Beck; A Blauvelt; E L Simpson; Z Chen; Q Chen; B Shumel; F A Khokhar; T Hultsch; E Rizova; A B Rossi; N M H Graham; G Pirozzi; Y Lu; M Ardeleanu
Journal:  Br J Dermatol       Date:  2019-12-01       Impact factor: 9.302
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.